ABVC ABVC BioPharma, Inc.
Healthcare$1.14+1.45%ClosedMarket Cap: $16.5M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
2.69
P/S
-20.75
EV/EBITDA
-2.10
DCF Value
$-0.12
FCF Yield
-20.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
111.6%
Operating Margin
1108.9%
Net Margin
1183.8%
ROE
-92.0%
ROA
-47.8%
ROIC
-56.7%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-1.6M | $-1.6M | $— | — |
| Q4 null | $-796.0K | 100.0% | $-3.0M | $-3.6M | $— | — |
| FY null | $0.00 | NaN% | $-7.2M | $-7.9M | $— | — |
| Q3 null | $0.00 | NaN% | $-2.0M | $-2.0M | $— | — |
| Q2 null | $0.00 | NaN% | $-2.3M | $-2.3M | $— | — |
| Q1 null | $0.00 | NaN% | $-693.0K | $-842.1K | $— | — |
| Q4 null | $2.0K | 100.0% | $-334.2K | $229.3K | $— | — |
| FY null | $509.6K | 99.9% | $-4.7M | $-4.9M | $— | — |
| Q3 null | $389.3K | 99.9% | $49.9K | $-186.6K | $— | — |
| Q2 null | $117.1K | 99.8% | $-860.1K | $-942.3K | $— | — |
| Q1 null | $1.2K | 77.0% | $-2.8M | $-2.8M | $— | — |
| Q4 2023 | $2.2K | -6329.8% | $-2.0M | $-3.1M | $-0.44 | — |